Benzinga | Dec 20, 2021 06:23AM EST

HC Wainwright & Co. Maintains Buy on Calliditas Therapeutics, Raises Price Target to $62

HC Wainwright & Co. analyst Edwin Zhang maintains Calliditas Therapeutics (NASDAQ:CALT) with a Buy and raises the price target from $52 to $62.